The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

New research reveals that taking a GLP-1 can be equivalent to '10 years of ageing' on the body, if proper precautions aren't taken ...

One in 20 Brits taking Mounjaro or Wegovy weight loss medications have been advised to avoid festive foods like pigs in ...

Wegovy jab users face regaining the weight they have lost, with patients finding themselves blocked from getting further ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...